Weight loss treatments linked to lower risk of obesity-related cancers in people without diabetes

Article excerpt

A study of 229,000 obese Americans without diabetes found that GLP-1 receptor agonists, drugs like semaglutide and tirzepatide marketed for weight loss, were associated with a 41% decrease in the overall risk of developing obesity-related cancers. The research, which compared patients using these medications to those not taking them, suggests that weight loss drugs may offer protective effects beyond their primary purpose of reducing body weight. The findings add to growing evidence that these increasingly popular treatments carry benefits beyond cosmetic weight reduction, though researchers cautioned about the need for longer-term studies to confirm the results.